Loss narrows modestly. Dyne Therapeutics reported a loss of $0.76 per share for Q4 2025. The biotech posted a narrower loss than expected by 4.4%, marking sequential improvement from the prior quarter’s $0.76 loss. Shares surged 11.8% to $19.78 on volume of 5.6 million, suggesting investors view the narrowing trajectory favorably despite the pre-revenue stage.
No revenue yet. The company reported zero revenue for the quarter, consistent with its clinical-stage profile. Operating loss totaled $116.1 million, driven primarily by $95.4 million in research and development expenses as the company advances its pipeline. The net loss of $112 million reflects ongoing investment in drug development programs. Operating cash flow was negative $111.8 million, with free cash flow at negative $112.3 million after $484,000 in capital expenditures.
Balance sheet remains solid. Dyne closed the quarter with $893.4 million in cash and equivalents against total debt of $169.2 million, providing a comfortable net cash position of $724.2 million. Working capital stood at $1.08 billion, offering substantial runway for clinical programs. The company raised $49.5 million in debt during the quarter, supplementing its cash position. With a market cap of $3.26 billion and 165 million shares outstanding, the balance sheet strength provides flexibility to fund operations through key clinical milestones.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.